124 related articles for article (PubMed ID: 1334011)
1. Assessment of liver function using a novel galactose single point method.
Tang HS; Hu OY
Digestion; 1992; 52(3-4):222-31. PubMed ID: 1334011
[TBL] [Abstract][Full Text] [Related]
2. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis.
Hu OY; Tang HS; Chang CL
J Clin Pharmacol; 1995 Mar; 35(3):250-8. PubMed ID: 7608313
[TBL] [Abstract][Full Text] [Related]
3. The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function.
Hu OY; Tang HS; Chang CL
Biopharm Drug Dispos; 1994 Oct; 15(7):563-76. PubMed ID: 7849232
[TBL] [Abstract][Full Text] [Related]
4. Quantitative rat liver function test by galactose single point method.
Young TH; Tang HS; Chao YC; Lee HS; Hsiong CH; Pao LH; Hu OY
Lab Anim; 2008 Oct; 42(4):495-504. PubMed ID: 18840618
[TBL] [Abstract][Full Text] [Related]
5. Effects of hyperglycemia on quantitative liver functions by the galactose load test in diabetic rats.
Young TH; Tang HS; Lee HS; Hsiong CH; Hu OY
Metabolism; 2007 Sep; 56(9):1265-9. PubMed ID: 17697871
[TBL] [Abstract][Full Text] [Related]
6. Uncertainty in liver function assessment on the basis of single-point galactose concentration.
Fabbri A; Bianchi G; Brizi M; Zoli M; Marchesini G
Digestion; 1997; 58(4):379-83. PubMed ID: 9324166
[TBL] [Abstract][Full Text] [Related]
7. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis.
Lindskov J
Acta Med Scand; 1982; 212(5):303-8. PubMed ID: 7180580
[TBL] [Abstract][Full Text] [Related]
8. Changes in Red Blood Cell Distribution Width is Associated with Liver Function Parameters and Prognosis in Patients with Chronic HBV Liver Disease.
Kai Y; Zishu G; Shihe G; Yufeng G; Qiang Z
Clin Lab; 2016 Nov; 62(11):2197-2202. PubMed ID: 28164679
[TBL] [Abstract][Full Text] [Related]
9. The quantitative liver function as measured by the galactose elimination capacity. I. Diagnostic value and relations to clinical, biochemical, and histological findings in patients with steatosis and patients with cirrhosis.
Lindskov J
Acta Med Scand; 1982; 212(5):295-302. PubMed ID: 7180579
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity.
Marchesini G; Fabbri A; Bugianesi E; Bianchi GP; Marchi E; Zoli M; Pisi E
Liver; 1990 Apr; 10(2):65-71. PubMed ID: 2352456
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study.
Addario L; Scaglione G; Tritto G; Di Costanzo GG; De Luca M; Lampasi F; Galeota Lanza A; Picciotto FP; Tartaglione MT; Utech W; Macr M; Giannelli E; Ascione A
Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):713-20. PubMed ID: 16772827
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
13. Soluble Vascular Endothelial Growth Factor Receptor-2 as a Predictive Factor for Progression of Illness in Chronic Liver Diseases and Hepatocellular Carcinoma.
Ratnasari N; Nurdjanah S; Sadewa AH; Hakimi M; Yano Y
Kobe J Med Sci; 2015 Dec; 61(3):E89-96. PubMed ID: 27323788
[TBL] [Abstract][Full Text] [Related]
14. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of hepatocellular carcinoma in patients with liver cirrhosis using liver function assays.
Itoshima T; Kawaguchi K; Ukida M; Ito T; Hattori S; Kitadai M; Ogawa H; Mizutani S; Kita K; Tanaka R
Acta Med Okayama; 1984 Apr; 38(2):159-68. PubMed ID: 6203337
[TBL] [Abstract][Full Text] [Related]
16. Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound-Toward Improved Detection of Liver Impairment.
Ferrandino G; Orf I; Smith R; Calcagno M; Thind AK; Debiram-Beecham I; Williams M; Gandelman O; de Saedeleer A; Kibble G; Lydon AM; Mayhew CA; Allsworth M; Boyle B; van der Schee MP; Allison M; Hoare M; Snowdon VK
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00239. PubMed ID: 33094960
[TBL] [Abstract][Full Text] [Related]
17. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
18. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.
Mondal G; Saroha A; Bose PP; Chatterjee BP
Glycoconj J; 2016 Apr; 33(2):209-18. PubMed ID: 27034286
[TBL] [Abstract][Full Text] [Related]
19. The value of liver function tests in hepatocellular carcinoma.
Lopez JB; Balasegaram M; Thambyrajah V; Timor J
Malays J Pathol; 1996 Dec; 18(2):95-9. PubMed ID: 10879229
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of the serial determination of galactose elimination capacity in chronic active hepatitis].
Aebli N; Reichen J
Schweiz Med Wochenschr; 1991 Jun; 121(26):970-6. PubMed ID: 1862313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
